B+
Bull case
20%
Probability
Target price
$2.00
Analysis reference price unavailable
Analysis 2026-07-28 · RankAlpha Sentiment Codex
ENVB
Enveric BiosciencesBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
EB-003 is advancing toward the clinic, with additional preclinical receptor-signaling and phototoxicity data supporting continued development. Patent expansion and recent financing provide strategic and operational optionality [#SEC-8K-2026-05-15] [#PR-EARNINGS-2026-05-19].
Posture
Constructive
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta +0.0.
What can break
Additional financing, warrant exercise, and private-placement activity may dilute shareholders [#SEC-8K-2026-05-15].
Momentum
97
Value
58
Sentiment
48
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $1.35 · Bull $2.00 · Bear $0.70Analysis 2026-07-28; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-10-27 • Vendor: Data Vendor v1
Scores
As of 2026-10-27 • Model: HYBRID_IC_RP
AI Memo
As of 2026-07-28 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-10-27
Investment thesis
As of 2026-10-27
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-10-27. Definitions
Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net Neutral
Target $120.00
Why
Momentum97 · Δ7d -
Value58 · Δ7d +0.0
Sentiment48 · Δ7d -
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Confirming evidence
- • Value remains the lead driver in the composite, 7D delta +0.0.
Contradictions & invalidation
- • Additional financing, warrant exercise, and private-placement activity may dilute shareholders [#SEC-8K-2026-05-15].
- • EB-003 remains preclinical; positive safety and mechanistic findings may not translate into human efficacy or regulatory success [#PR-EARNINGS-2026-05-19].
- • The thesis remains dependent on a future IND and human clinical execution.
Catalyst clock
2026-10-26
EB-003 IND-enabling progression
Lead driver: Value · See fundamentals
Momentum
97
8% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Value
58
47% active weight
Current posture
7d trendFlat
Δ7d
+0.0
Δ21d
-0.3
Sentiment
48
45% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade
Composite grade B. Momentum 96.8 / Value 58.0 / Sentiment 48.3
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-07-28. Scenario method
Most likely
B
Base case
50%
Probability
Target price
$1.35
Analysis reference price unavailable
Analysis 2026-07-28 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$0.70
Analysis reference price unavailable
Analysis 2026-07-28 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-10-27
Fundamentals (TTM)
As of 2026-10-27
Market Cap
$6.36M
Beta
0.28
Shares Out
4.48M
P/E (TTM) · Derived
-0.0
P/S (TTM)
-
P/FCF (TTM) · Derived
-0.14
Rev YoY
-100.0%
EPS YoY
-93.5%
Gross Margin
+12.7%
Op Margin
-
Net Debt
-$4.68M
Current Ratio
10.21
As of 2026-10-27 • Updated nightlySource: Internal modelMethods & Data